Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COEP Coeptis Therapeutics	$9.54 +5.2%	$9.52	$2.31 ▼ $13.70	$33.51M	-0.66	117,372 shs	1,680 shs
FTLF FitLife Brands	$14.97 +4.1%	$13.55	$9.83 ▼ $17.75	$140.58M	0.9	17,646 shs	7,984 shs
RAPT RAPT Therapeutics	$0.94 -3.0%	$0.97	$0.71 ▼ $4.60	$125.81M	-0.04	1.28 million shs	142,274 shs
SLN Silence Therapeutics	$5.69 +9.7%	$3.52	$1.97 ▼ $22.47	$170.57M	1.2	264,352 shs	43,920 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COEP Coeptis Therapeutics	-1.41%	-7.65%	+1.00%	-13.38%	+70.30%
FTLF FitLife Brands	-0.42%	+3.45%	-0.28%	-1.44%	-6.74%
RAPT RAPT Therapeutics	-0.30%	+9.56%	+5.62%	-10.74%	-76.13%
SLN Silence Therapeutics	+3.80%	+0.97%	+48.29%	+9.96%	-76.51%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
COEP Coeptis Therapeutics	1.1386 of 5 stars	0.0	5.0	0.0	2.6	1.7	0.0
FTLF FitLife Brands	4.43 of 5 stars	3.7	5.0	0.0	2.0	3.3	3.1
RAPT RAPT Therapeutics	3.8159 of 5 stars	3.2	1.0	4.2	2.6	1.7	1.3
SLN Silence Therapeutics	3.7314 of 5 stars	4.4	4.0	0.0	3.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
COEP Coeptis Therapeutics	2.00	Hold	N/A	N/A
FTLF FitLife Brands	3.33	Buy	$20.50	36.94% Upside
RAPT RAPT Therapeutics	2.33	Hold	$3.00	217.80% Upside
SLN Silence Therapeutics	2.71	Moderate Buy	$33.83	494.19% Upside

Current Analyst Ratings Breakdown

Latest COEP, SLN, FTLF, and RAPT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/22/2025	RAPT RAPT Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$2.00 ➝ $1.00
5/22/2025	RAPT RAPT Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$6.00
5/9/2025	SLN Silence Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sell ➝ Sell	$4.00 ➝ $3.00
5/9/2025	SLN Silence Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$45.00 ➝ $25.00
5/9/2025	SLN Silence Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$55.00 ➝ $35.00
3/17/2025	FTLF FitLife Brands	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$21.00
3/10/2025	RAPT RAPT Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
3/7/2025	SLN Silence Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $75.00
3/5/2025	SLN Silence Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$49.00 ➝ $45.00
3/4/2025	SLN Silence Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$67.00 ➝ $25.00
3/4/2025	SLN Silence Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sell ➝ Sell	$6.00 ➝ $4.00

(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
COEP Coeptis Therapeutics	$62.87K	532.91	N/A	N/A	$0.48 per share	19.86
FTLF FitLife Brands	$63.86M	2.20	$0.79 per share	19.05	$3.04 per share	4.92
RAPT RAPT Therapeutics	$1.53M	81.62	N/A	N/A	$4.27 per share	0.22
SLN Silence Therapeutics	$27.70M	6.15	N/A	N/A	$0.71 per share	8.02

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
COEP Coeptis Therapeutics	-$21.27M	-$5.80	N/A	∞	N/A	N/A	-1,094.50%	-219.97%	N/A
FTLF FitLife Brands	$5.30M	$0.84	17.72	13.61	N/A	13.38%	28.03%	15.13%	N/A
RAPT RAPT Therapeutics	-$116.80M	-$2.40	N/A	N/A	N/A	N/A	-89.10%	-76.13%	8/14/2025 (Estimated)
SLN Silence Therapeutics	-$53.82M	-$1.50	N/A	N/A	N/A	-342.00%	-62.81%	-33.89%	N/A

Latest COEP, SLN, FTLF, and RAPT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	FTLF FitLife Brands	$0.24	$0.20	-$0.04	$0.20	N/A	N/A
5/14/2025	Q1 2025	COEP Coeptis Therapeutics	N/A	-$1.11	N/A	-$1.11	N/A	N/A
5/8/2025	Q1 2025	RAPT RAPT Therapeutics	-$0.31	-$0.08	+$0.23	-$0.08	N/A	N/A
5/8/2025	Q1 2025	SLN Silence Therapeutics	-$0.18	-$0.60	-$0.42	-$0.60	$3.58 million	$0.14 million
3/27/2025	Q4 2024	FTLF FitLife Brands	$0.22	$0.21	-$0.01	N/A	N/A	N/A
3/6/2025	Q4 2024	RAPT RAPT Therapeutics	-$0.45	-$1.14	-$0.69	-$1.14	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
COEP Coeptis Therapeutics	N/A	N/A	N/A	N/A	N/A
FTLF FitLife Brands	N/A	N/A	N/A	N/A	N/A
RAPT RAPT Therapeutics	N/A	N/A	N/A	N/A	N/A
SLN Silence Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
COEP Coeptis Therapeutics	0.03	0.40	0.40
FTLF FitLife Brands	0.28	1.50	0.64
RAPT RAPT Therapeutics	N/A	9.90	9.90
SLN Silence Therapeutics	N/A	9.31	9.31

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
COEP Coeptis Therapeutics	13.88%
FTLF FitLife Brands	2.32%
RAPT RAPT Therapeutics	99.09%
SLN Silence Therapeutics	98.73%

Insider Ownership

Company	Insider Ownership
COEP Coeptis Therapeutics	24.25%
FTLF FitLife Brands	61.30%
RAPT RAPT Therapeutics	2.36%
SLN Silence Therapeutics	2.95%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
COEP Coeptis Therapeutics	2	3.51 million	2.46 million	Not Optionable
FTLF FitLife Brands	20	9.39 million	3.56 million	Not Optionable
RAPT RAPT Therapeutics	80	132.29 million	32.65 million	Optionable
SLN Silence Therapeutics	100	29.93 million	N/A	Not Optionable

COEP, SLN, FTLF, and RAPT Headlines

Recent News About These Companies

Silence Therapeutics plc (NASDAQ:SLN) Shares Bought by Woodline Partners LP

May 27 at 4:38 AM | marketbeat.com

Point72 Asset Management L.P. Has $4.36 Million Stock Position in Silence Therapeutics plc (NASDAQ:SLN)

May 22, 2025 | marketbeat.com

Wall Street Analysts Believe Silence Therapeutics (SLN) Could Rally 590.66%: Here's is How to Trade

May 21, 2025 | zacks.com

Silence Therapeutics plc (NASDAQ:SLN) Receives Average Recommendation of "Moderate Buy" from Analysts

May 15, 2025 | marketbeat.com

Integral Health Asset Management LLC Takes Position in Silence Therapeutics plc (NASDAQ:SLN)

May 14, 2025 | marketbeat.com

What is William Blair's Forecast for SLN FY2027 Earnings?

May 14, 2025 | marketbeat.com

Silence Therapeutics (NASDAQ:SLN) Price Target Lowered to $35.00 at Chardan Capital

May 11, 2025 | marketbeat.com

Silence Therapeutics (SLN) Projected to Post Quarterly Earnings on Thursday

May 10, 2025 | marketbeat.com

Silence Therapeutics plc GAAP EPS of -C$0.20

May 8, 2025 | seekingalpha.com

Cantor Fitzgerald L. P. Buys 205,534 Shares of Silence Therapeutics plc (NASDAQ:SLN)

May 7, 2025 | marketbeat.com

Silence Therapeutics plc: Silence Therapeutics Welcomes Tim McInerney to Board of Directors

May 6, 2025 | finanznachrichten.de

Silence Therapeutics Welcomes Tim McInerney to Board of Directors

May 6, 2025 | businesswire.com

Silence Therapeutics plc (NASDAQ:SLN) Stock Holdings Increased by Nantahala Capital Management LLC

April 30, 2025 | marketbeat.com

Boothbay Fund Management LLC Has $2.42 Million Position in Silence Therapeutics plc (NASDAQ:SLN)

April 30, 2025 | marketbeat.com

Silence Therapeutics plc (SLN): Among Takeover Rumors Hedge Funds Are Buying

April 23, 2025 | insidermonkey.com

Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference

March 5, 2025 | businesswire.com

Silence Therapeutics (SLN) Upgraded to Buy: Here's What You Should Know

March 4, 2025 | zacks.com

Silence Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

March 1, 2025 | uk.finance.yahoo.com

Silence Therapeutics plc (SLN) Q4 2024 Earnings Call Transcript

February 28, 2025 | seekingalpha.com

Silence Quiets Phase III Pace for Lipoprotein Drug, Seeks Partner

February 28, 2025 | biospace.com

Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

February 27, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

COEP, SLN, FTLF, and RAPT Company Descriptions

Coeptis Therapeutics NASDAQ:COEP

$9.54 +0.48 (+5.24%)

As of 11:30 AM Eastern

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

FitLife Brands NASDAQ:FTLF

$14.97 +0.59 (+4.10%)

As of 11:36 AM Eastern

FitLife Brands, Inc. provides nutritional supplements for health-conscious consumers in the United States and internationally. The company provides weight loss, sports nutrition, and general health products; sports nutrition products; weight loss and sports nutrition products; sports nutrition and general wellness formulations with an emphasis on natural, vegan, and organic ingredients; and male health and weight loss products, as well as other diet, health, and sports nutrition supplements and related products; and value-oriented sports nutrition and weight loss products. It offers MRC products which includes general health supplements; and natural skincare and beauty products. In addition, it markets its products under the brand names of NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, Metis Nutrition, iSatori, BioGenetic Laboratories, Energize, Dr. Tobias, All-Natural Advice, and Maritime Naturals through franchised stores, as well as through retail locations, which include specialty, mass, and online. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska.

RAPT Therapeutics NASDAQ:RAPT

$0.94 -0.03 (-2.97%)

As of 11:38 AM Eastern

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company

Silence Therapeutics NASDAQ:SLN

$5.69 +0.50 (+9.71%)

As of 11:38 AM Eastern

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time